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Background
One of the novel approaches to increase vaccine efficacy is
to target antigens directly to dendritic cells (DC) in lym-
phoid tissues. C-type lectin receptors are expressed at the
DC surface and are used as markers of DC subsets. In this
aim, we have developed recombinant fusion proteins
associating HIV Gag p24 with mAbs specific for DC sur-
face receptors such as Langerin, DCIR and LOX-1. Our
purpose is to understand which DC receptors are most
favourable to target for cellular, humoral, or mixed
immune responses.
Methods
Non human primates were primed with nanoparticules
coated with p24 (p24-PLA) then boosted with anti-Lang-
erin, anti-DCIR or anti-LOX-1 recombinant vaccines fused
to p24. A control group of animals were boosted with
p24-PLA. Immuno-monitoring of animals was focused on
p24 specific T cell responses and the production of spe-
cific antibodies in serum.
Results
Anti-Langerin and anti-DCIR mAb-based vaccines elicited
comparable p24 specific T cell responses, whereas the
anti-LOX-1-based vaccine induced relatively poor T cell
responses. By contrast, robust antibody responses were
detected in sera from animals of the LOX-1 group and
lower levels were detected in animals of the Langerin
group. Animals from the DCIR group presented antibody
responses similar to animals from the LOX-1 group.
Conclusion
Although these studies need to be extended to priming
immunity, this work showed that targeting vaccine anti-
gen to Langerin+ DC favoured the induction of T cell
responses whereas targeting LOX-1+ DC favoured the
induction of antibody responses.
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